论文部分内容阅读
目的:评价多西他赛(Doc)联合氟脲嘧啶类药物二线治疗非小细胞肺癌(NSCLC)的疗效及毒副反应。方法:一线方案化疗失败的晚期NSCLC患者,第一阶段入组病例给予Doc75mg/m2,静滴1h,第一天;5-氟脲嘧啶(5-Fu)200mg/m2,静滴4h,第1～14天;第二阶段入组病例给予Doc75mg/m2,静滴,第一天;卡培他滨(Capecitabine)2000mg/m2.d-1,分两次餐后口服,第1～14天。均为每21d重复。主要观察终点为总生存时间。结果:15例可评价疗效,18例可评价毒副反应。部分缓解(PR)和完全缓解(CR)各3、0例,有效率(CR+PR)20.0;5例(33.3)获稳定(SD)。中位肿瘤无进展时间6.2个月,中位生存时间10.4个月。2例(11.1)出现Ⅲ度中性粒细胞下降。Ⅲ度非血液毒性包括腹泻(16.7)、乏力(16.7)、恶心(16.7)和口腔炎(11.1)。手足综合征轻微且少见。结论:Doc联合氟脲嘧啶类药物对晚期NSCLC具有较好的抗癌活性,安全性好,值得在前瞻性随机对照试验中进一步研究。
Objective: To evaluate the efficacy and side effects of docetaxel combined with fluorouracil in the second-line treatment of non-small cell lung cancer (NSCLC). Methods: Patients with advanced NSCLC who failed first-line chemotherapy were enrolled in the first phase of the study. Patients in the first phase were given Doc 75 mg / m 2 intravenously for 1 hour on the first day. After 5-fluorouracil (200 mg / m 2) ~ 14 days; the second phase of the group were given Doc75mg / m2, intravenous infusion, the first day; capecitabine (Capecitabine) 2000mg / m2.d-1, two times after oral administration, the first to 14 days. Every 21d repeat. The primary end point was total survival time. Results: Fifteen patients could evaluate the curative effect and 18 patients could evaluate the side effects. Partial response (PR) and complete remission (CR) 3,0 cases, the effective rate (CR + PR) 20.0; 5 cases (33.3) were stable (SD). The median tumor progression time of 6.2 months, the median survival time of 10.4 months. 2 cases (11.1) Ⅲ degree neutropenia. Grade III non-hematologic toxicity included diarrhea (16.7), weakness (16.7), nausea (16.7) and stomatitis (11.1). Hand-foot syndrome is mild and uncommon. Conclusion: Doc combination with fluorouracil has good anticancer activity in advanced NSCLC and its safety is good. It is worth further investigation in a prospective randomized controlled trial.